Reply to the letter "Body mass index and clinical outcomes in trastuzumab-treated metastatic breast cancer patients: An alternative explanation for the lack of association".

Reply to the letter "Body mass index and clinical outcomes in trastuzumab-treated metastatic breast cancer patients: An alternative explanation for the lack of association". Breast. 2018 Mar 16;: Authors: Poletto E, Martel S, Lambertini M, Puglisi F PMID: 29555407 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29555407?dopt=Abstract

Source: Breast - March 16, 2018 Category: Cancer & Oncology Authors: Poletto E, Martel S, Lambertini M, Puglisi F Tags: Breast Source Type: research

More News: Breast Cancer | Cancer | Cancer & Oncology | Herceptin